A Phase 2 interventional study of Docetaxel and Feladilimab in Neoplasms, sponsored by GlaxoSmithKline. Completed at 43 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-19.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is a sub-study of the master protocol 205801 (NCT03739710). This sub study has assessed the clinical activity of novel regimen (Feladilimab plus Docetaxel) with SOC (Docetaxel) in participants with NSCLC.
10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's enrollment of 105 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants with or cytologically confirmed diagnosis of NSCLC (squamous or non-squamous) and
a) Documented disease progression based on radiographic imaging, during or after a maximum of 2 for locally/regionally advanced recurrent, Stage IIIb/Stage IIIc/Stage IV or disease. Two components of treatment must have been received in the same line or as separate lines of therapy: i) No more than or less than 1 line of platinum-containing chemotherapy regimen, and ii) No more than or less than 1 line of Programmed cell death ligand 1 (PD[L]1) monoclonal antibody (mAb) containing regimen.
b) Participants with known BRAF molecular alterations must have had disease progression after receiving the locally available SoC treatment for the molecular alteration.
c) Participants who received prior anti-PD(L)1 therapy must fulfill the following requirements: i) Have achieved a CR, PR or SD and subsequently had disease progression (per 1.1 criteria) either on or after completing PD(L)1 therapy ii) Have not progressed or recurred within the first 12 weeks of PD(L)1 therapy, either clinically or per RECIST 1.1 criteria
A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions apply:
i) Not a woman of (WOCBP) or ii) A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 120 days after the last dose of study treatment.
Exclusion Criteria:
Participants who received prior treatment with the following therapies (calculation is based on date of last therapy to date of first dose of study treatment):
Invasive or history of invasive malignancy other than disease under study within the last 2 years, except
Toxicity from previous anticancer treatment that includes:
History or evidence of cardiac abnormalities within the 6 months prior to enrollment which include
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Docetaxel
Drug: Docetaxel · Drug: Feladilimab
Docetaxel was administered as IV infusion.
Feladilimab was administered as IV infusion.
Overall Survival
Overall survival was calculated as time from randomization to death. Confidence Intervals estimated using the Brookmeyer Crowley method.
Time frame: Up to 2 years
Kaplan-Meier Estimates of Overall Survival at 12 and 18 Months
Overall survival was defined as the time between date of randomization and death due to any cause. Kaplan-Meier estimates of the percentage of participants who died at each time point was calculated. Confidence Intervals estimated using the Brookmeyer Crowley method.
Time frame: Month 12 and 18
Number of Participants With Complete Response (CR), Partial Response (PR), Stable Disease (SD), Progressive Disease (PD) or Not Evaluable
CR, PR, SD and PD will be evaluated as per RECIST version 1.1 criteria. Complete Response (CR) was defined as disappearance of all target and non target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. Partial Response (PR) was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline). Stable Disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. Progressive Disease was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5mm.
Time frame: Up to 2 years
Kaplan-Meier Estimates of Progression-Free Survival (PFS)
PFS is defined as time from the date of randomization to the date of disease progression as per RECIST v1.1. or death whichever occurs earlier. Progressive Disease was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5mm. Confidence Intervals estimated using the Brookmeyer Crowley method.
Time frame: Up to 2 years
Objective Response Rate
ORR was calculated as the percentage of participants with a confirmed complete response (CR) or partial response (PR) relative to the total number of participants in the analysis population per response evaluation criteria in solid tumors (RECIST) version (v)1.1. Complete Response (CR) was defined as disappearance of all target and non target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. Partial Response (PR) was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.
Time frame: Up to 2 years
Kaplan-Meier Estimates of Duration of Response (DOR) in Participants With Objective Response
DOR is defined as the time for first documented evidence of CR or PR until disease progression or death, per RECIST 1.1 criteria. Complete Response (CR) was defined as disappearance of all target and non target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. Partial Response (PR) was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. Confidence Intervals estimated using the Brookmeyer Crowley method.
Time frame: Up to 2 years
Disease Control Rate (DCR)
DCR is defined as the percentage of participants with a confirmed CR + PR at any time, plus SD =\>12 weeks as per RECIST v1.1. Complete Response (CR) was defined as disappearance of all target and non target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. Partial Response (PR) was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline). Stable Disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease.
Time frame: Up to 2 years
Number of Participants With iRECIST Complete Response (iCR), Partial Response (iPR), Unconfirmed Progressive Disease (iUPD), Confirmed Progressive Disease (iCPD), Stable Disease (iSD) or Not Evaluable
Modified RECIST 1.1 for immune-based therapeutics (iRECIST) is based on RECIST v 1.1 but adapted to account for the unique tumor response seen with immunotherapeutic drugs. iRECIST was used to assess tumor response and progression and make treatment decisions. iCR: disappearance of all target lesions; iPR: at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline). iCPD: either 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; iSD: stable disease in the absence of CR or PD and iUPD: unconfirmed progressive disease when PD is unconfirmed and NE: not evaluable.
Time frame: Up to 2 years
Kaplan-Meier Estimates of iRECIST Progression-free Survival (iPFS)
iPFS is defined as time from the date of randomization to the date of disease progression or death, whichever occurs earlier, per iRECIST criteria. Progressive Disease was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5mm. Confidence Intervals estimated using the Brookmeyer Crowley method.
Time frame: Up to 2 years
iRECIST Objective Response Rate (iORR)
iORR is defined as the percentage of participants with a confirmed iCR or iPR at any time per iRECIST criteria. iCR was defined as disappearance of all target and non target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. iPR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.
Time frame: Up to 2 years
Kaplan-Meier Estimates of iRECIST Duration of Response (iDOR) in Participants With Objective Response
iDOR is defined as the time from first documented evidence of CR or PR until disease progression or death, per iRECIST criteria. iCR was defined as disappearance of all target and non target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. iPR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. Confidence Intervals estimated using the Brookmeyer Crowley method.
Time frame: Up to 2 years
Number of Participants With AEs, Adverse Events of Special Interest (AESI), SAEs and AE/SAEs Leading to Dose Modifications/Delays/Withdrawals
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE was defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, any other situation such as important medical events according to medical or scientific judgement. AESI are considered to be Infusion Related Reactions (IRRs) and those of potential immunologic etiology.
Time frame: Up to 2 years
Number of Participants With Maximum Grade Increase in Clinical Chemistry Parameters at Worst Case Post-Baseline
Blood samples were collected for assessment of the clinical chemistry parameters. Laboratory grades were evaluated using the Common Terminology Criteria for Adverse Events (CTCAE v5.0). Grade 1 = Mild AE; Grade 2 = Moderate AE; Grade 3 = Severe AE; Grade 4 = Life-threatening or disabling AE. Number of participants with clinical chemistry results by maximum grade increase (Increase to Grade 3 or Increase to Grade 4) are presented.
Time frame: Up to 2 years
Number of Participants With Maximum Grade Increase in Hematology Parameters at Worst Case Post-Baseline
Blood samples were collected for assessment of the hematology parameters. Laboratory grades were evaluated using the Common Terminology Criteria for Adverse Events (CTCAE v5.0). Grade 1 = Mild AE; Grade 2 = Moderate AE; Grade 3 = Severe AE; Grade 4 = Life-threatening or disabling AE. Number of participants with Hematology results by maximum grade increase (Increase to Grade 3 or Increase to Grade 4) are presented.
Time frame: Up to 2 years
Number of Participants With Maximum Grade Increase in Vital Signs (Systolic Blood Pressure and Diastolic Blood Pressure) Parameters at Worst Case Post-Baseline
Blood Pressure was measured after 5 minutes of rest and was taken in the same position throughout the study. Laboratory grades were evaluated using the Common Terminology Criteria for Adverse Events (CTCAE v5.0). Grade 1 = Mild AE; Grade 2 = Moderate AE; Grade 3 = Severe AE. Number of participants with vital signs results by maximum grade increase (Increase to Grade 2 or Increase to Grade 3) are presented.
Time frame: Up to 2 years
Number of Participants With Vital Signs (Temperature) Parameter Results at Worst Case Post-Baseline
Body temperature was measured after 5 minutes of rest. Results are presented in the following categories: Decrease to \<=35 Degrees Celsius, Change to Normal or No Change and Increase to \>=38 Degrees Celsius.
Time frame: Up to 2 years
Number of Participants With Vital Signs (Pulse Rate) Parameter Results at Worst Case Post-Baseline
Pulse Rate was measured after 5 minutes of rest. Results are presented in the following categories: Decrease to \<50 beats per minute, Change to Normal or No Change and Increase to \>120 beats per minute.
Time frame: Up to 2 years
Minimum Observed Concentration (CmIn) of Feladilimab
Blood samples were collected for assessment of the pharmacokinetic parameters.
Time frame: Week 1
Maximum Observed Concentration (Cmax) of Feladilimab
Blood samples were collected for assessment of the pharmacokinetic parameters.
Time frame: Week 1, Week 13 and Week 25
Maximum Observed Concentration (Cmax) of Docetaxel
Blood samples were collected for assessment of the pharmacokinetic parameters.
Time frame: Week 1, Week 4, Week 7, Week 10, Week 13, Week 16, Week 19 and Week 22
Number of Participants With Positive Anti-drug Antibodies (ADA) Against Docetaxel
Time frame: Up to 2 years
Number of Participants With Positive ADA Against Feladilimab
Time frame: Week 1, 4, 7, 10, 13, 16, 19, 22, 25, 37, 49, 61 and 73
| Milestone | Docetaxel 75 mg/m^2 | Feladilimab 80 mg Plus Docetaxel 75 mg/m^2 |
|---|---|---|
| Started | 35 | 70 |
| Completed | 0 | 0 |
| Not completed | 35 | 70 |
| Withdrew: Death | 25 | 62 |
| Withdrew: Site closed | 6 | 6 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Withdrawal by subject | 3 | 2 |
Overall survival was calculated as time from randomization to death. Confidence Intervals estimated using the Brookmeyer Crowley method.
| Months | Docetaxel 75 mg/m^2 | Feladilimab 80 mg Plus Docetaxel 75 mg/m^2 |
|---|---|---|
| Overall Survival | 8.2 (4.5 to 16.1) | 7.8 (4.7 to 10.8) |
Overall survival was defined as the time between date of randomization and death due to any cause. Kaplan-Meier estimates of the percentage of participants who died at each time point was calculated. Confidence Intervals estimated using the Brookmeyer Crowley method.
| Percentage of Participants | Docetaxel 75 mg/m^2 | Feladilimab 80 mg Plus Docetaxel 75 mg/m^2 |
|---|---|---|
| Month 12 | 44 (27 to 60) | 28 (18 to 39) |
| Month 18 | 28 (14 to 44) | 18 (10 to 28) |
CR, PR, SD and PD will be evaluated as per RECIST version 1.1 criteria. Complete Response (CR) was defined as disappearance of all target and non target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. Partial Response (PR) was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline). Stable Disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. Progressive Disease was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5mm.
| Participants | Docetaxel 75 mg/m^2 | Feladilimab 80 mg Plus Docetaxel 75 mg/m^2 |
|---|---|---|
| Complete Response | 0 | 0 |
| Partial Response | 4 | 13 |
| Stable Disease | 10 | 22 |
| Progressive Disease | 14 | 23 |
| Not Evaluable | 7 | 12 |
PFS is defined as time from the date of randomization to the date of disease progression as per RECIST v1.1. or death whichever occurs earlier. Progressive Disease was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5mm. Confidence Intervals estimated using the Brookmeyer Crowley method.
| Months | Docetaxel 75 mg/m^2 | Feladilimab 80 mg Plus Docetaxel 75 mg/m2 |
|---|---|---|
| Kaplan-Meier Estimates of Progression-Free Survival (PFS) | 3.3 (1.6 to 4.2) | 3.4 (2.6 to 4.3) |
ORR was calculated as the percentage of participants with a confirmed complete response (CR) or partial response (PR) relative to the total number of participants in the analysis population per response evaluation criteria in solid tumors (RECIST) version (v)1.1. Complete Response (CR) was defined as disappearance of all target and non target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. Partial Response (PR) was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.
| Percentage of Participants | Docetaxel 75 mg/m^2 | Feladilimab 80 mg Plus Docetaxel 75 mg/m2 |
|---|---|---|
| Objective Response Rate | 11 (3.2 to 26.7) | 19 (10.3 to 29.7) |
DOR is defined as the time for first documented evidence of CR or PR until disease progression or death, per RECIST 1.1 criteria. Complete Response (CR) was defined as disappearance of all target and non target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. Partial Response (PR) was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. Confidence Intervals estimated using the Brookmeyer Crowley method.
| Months | Docetaxel 75 mg/m^2 | Feladilimab 80 mg Plus Docetaxel 75 mg/m^2 |
|---|---|---|
| Kaplan-Meier Estimates of Duration of Response (DOR) in Participants With Objective Response | 4.8 (2.8 to NA) | 4.3 (2.4 to 8.7) |
DCR is defined as the percentage of participants with a confirmed CR + PR at any time, plus SD =\>12 weeks as per RECIST v1.1. Complete Response (CR) was defined as disappearance of all target and non target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. Partial Response (PR) was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline). Stable Disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease.
| Percentage of Participants | Docetaxel 75 mg/m^2 | Feladilimab 80 mg Plus Docetaxel 75 mg/m^2 |
|---|---|---|
| Disease Control Rate (DCR) | 40 (23.9 to 57.9) | 50 (37.8 to 62.2) |
Modified RECIST 1.1 for immune-based therapeutics (iRECIST) is based on RECIST v 1.1 but adapted to account for the unique tumor response seen with immunotherapeutic drugs. iRECIST was used to assess tumor response and progression and make treatment decisions. iCR: disappearance of all target lesions; iPR: at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline). iCPD: either 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; iSD: stable disease in the absence of CR or PD and iUPD: unconfirmed progressive disease when PD is unconfirmed and NE: not evaluable.
| Participants | Docetaxel 75 mg/m^2 | Feladilimab 80 mg Plus Docetaxel 75 mg/m^2 |
|---|---|---|
| iCR | 0 | 0 |
| iPR | 4 | 13 |
| iUPD | 11 | 15 |
| iCPD | 3 | 8 |
| iSD | 10 | 22 |
| Not Evaluable | 7 | 12 |
iPFS is defined as time from the date of randomization to the date of disease progression or death, whichever occurs earlier, per iRECIST criteria. Progressive Disease was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5mm. Confidence Intervals estimated using the Brookmeyer Crowley method.
| Months | Docetaxel 75 mg/m^2 | Feladilimab 80 mg Plus Docetaxel 75 mg/m2 |
|---|---|---|
| Kaplan-Meier Estimates of iRECIST Progression-free Survival (iPFS) | 3.3 (1.6 to 4.2) | 3.4 (2.6 to 4.3) |
iORR is defined as the percentage of participants with a confirmed iCR or iPR at any time per iRECIST criteria. iCR was defined as disappearance of all target and non target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. iPR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.
| Percentage of Participants | Docetaxel 75 mg/m^2 | Feladilimab 80 mg Plus Docetaxel 75 mg/m^2 |
|---|---|---|
| iRECIST Objective Response Rate (iORR) | 11 (3.2 to 26.7) | 19 (10.3 to 29.7) |
iDOR is defined as the time from first documented evidence of CR or PR until disease progression or death, per iRECIST criteria. iCR was defined as disappearance of all target and non target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. iPR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. Confidence Intervals estimated using the Brookmeyer Crowley method.
| Months | Docetaxel 75 mg/m^2 | Feladilimab 80 mg Plus Docetaxel 75 mg/m^2 |
|---|---|---|
| Kaplan-Meier Estimates of iRECIST Duration of Response (iDOR) in Participants With Objective Response | 4.8 (2.8 to NA) | 4.3 (2.4 to 8.7) |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE was defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, any other situation such as important medical events according to medical or scientific judgement. AESI are considered to be Infusion Related Reactions (IRRs) and those of potential immunologic etiology.
| Participants | Docetaxel 75 mg/m^2 | Feladilimab 80 mg Plus Docetaxel 75 mg/m^2 |
|---|---|---|
| AEs | 34 | 70 |
| AESI | 1 | 4 |
| SAEs | 16 | 34 |
| AEs leading to permanent discontinuation of study treatment | 12 | 16 |
| AEs leading to dose reduction | 7 | 13 |
| AEs leading to dose interruption/delay | 11 | 24 |
Blood samples were collected for assessment of the clinical chemistry parameters. Laboratory grades were evaluated using the Common Terminology Criteria for Adverse Events (CTCAE v5.0). Grade 1 = Mild AE; Grade 2 = Moderate AE; Grade 3 = Severe AE; Grade 4 = Life-threatening or disabling AE. Number of participants with clinical chemistry results by maximum grade increase (Increase to Grade 3 or Increase to Grade 4) are presented.
| Participants | Docetaxel 75 mg/m^2 | Feladilimab 80 mg Plus Docetaxel 75 mg/m^2 |
|---|---|---|
| Blood bilirubin increased | 0 | 1 |
| Hypercalcemia | 0 | 2 |
| Creatinine increased | 0 | 1 |
Blood samples were collected for assessment of the hematology parameters. Laboratory grades were evaluated using the Common Terminology Criteria for Adverse Events (CTCAE v5.0). Grade 1 = Mild AE; Grade 2 = Moderate AE; Grade 3 = Severe AE; Grade 4 = Life-threatening or disabling AE. Number of participants with Hematology results by maximum grade increase (Increase to Grade 3 or Increase to Grade 4) are presented.
| Participants | Docetaxel 75 mg/m^2 | Feladilimab 80 mg Plus Docetaxel 75 mg/m^2 |
|---|---|---|
| Anemia | 2 | 5 |
| Leukocytosis | 0 | 1 |
| White blood cell decreased | 5 | 11 |
| Lymphocyte count decreased | 4 | 12 |
| Neutrophil count decreased | 4 | 13 |
| Platelet count decreased | 0 | 3 |
Blood Pressure was measured after 5 minutes of rest and was taken in the same position throughout the study. Laboratory grades were evaluated using the Common Terminology Criteria for Adverse Events (CTCAE v5.0). Grade 1 = Mild AE; Grade 2 = Moderate AE; Grade 3 = Severe AE. Number of participants with vital signs results by maximum grade increase (Increase to Grade 2 or Increase to Grade 3) are presented.
| Participants | Docetaxel 75 mg/m^2 | Feladilimab 80 mg Plus Docetaxel 75 mg/m^2 |
|---|---|---|
| Diastolic Blood Pressure | 12 | 26 |
| Systolic Blood Pressure | 16 | 28 |
Body temperature was measured after 5 minutes of rest. Results are presented in the following categories: Decrease to \<=35 Degrees Celsius, Change to Normal or No Change and Increase to \>=38 Degrees Celsius.
| Participants | Docetaxel 75 mg/m^2 | Feladilimab 80 mg Plus Docetaxel 75 mg/m^2 |
|---|---|---|
| Decrease to <=35 Degrees Celsius | 0 | 6 |
| Change to Normal or No Change | 33 | 52 |
| Increase to >=38 Degrees Celsius | 1 | 5 |
Pulse Rate was measured after 5 minutes of rest. Results are presented in the following categories: Decrease to \<50 beats per minute, Change to Normal or No Change and Increase to \>120 beats per minute.
| Participants | Docetaxel 75 mg/m^2 | Feladilimab 80 mg Plus Docetaxel 75 mg/m^2 |
|---|---|---|
| Decrease to <50 beats per minute | 0 | 0 |
| Change to Normal or No Change | 32 | 55 |
| Increase to >120 beats per minute | 2 | 8 |
Blood samples were collected for assessment of the pharmacokinetic parameters.
| nanogram per millimeter (ng/mL) | Feladilimab 80 mg Plus Docetaxel 75 mg/m^2 |
|---|---|
| Minimum Observed Concentration (CmIn) of Feladilimab | 6104.6 ± 91.3 |
Blood samples were collected for assessment of the pharmacokinetic parameters.
| nanogram per millimeter (ng/mL) | Feladilimab 80 mg Plus Docetaxel 75 mg/m^2 |
|---|---|
| Week 1 | 24923.7 ± 26.7 |
| Week 13 | 28715.9 ± 45.4 |
| Week 25 | 32688.4 ± 27.4 |
Blood samples were collected for assessment of the pharmacokinetic parameters.
| nanogram per millimeter (ng/mL) | Docetaxel 75 mg/m^2 | Feladilimab 80 mg Plus Docetaxel 75 mg/m^2 |
|---|---|---|
| Week 1 | 1500.9 ± 133.5 | 1429.9 ± 138.7 |
| Week 4 | 1587.1 ± 128.6 | 1399.7 ± 99.3 |
| Week 7 | 846.8 ± 166.4 | 1036.9 ± 171.2 |
| Week 10 | 1262.9 ± 155.4 | 1248.4 ± 118.3 |
| Week 13 | 1354.2 ± 212.1 | 1363.4 ± 137.8 |
| Week 16 | 1095.3 ± 114.3 | 1381.9 ± 114.0 |
| Week 19 | 759.0 ± 74.0 | 1765.7 ± 95.1 |
| Week 22 | 535.5 ± 10.9 | 2430.7 ± 73.3 |
No measurements were reported for this outcome.
| Participants | Feladilimab 80 mg Plus Docetaxel 75 mg/m^2 |
|---|---|
| Week 1 | 1 |
| Week 4 | 8 |
| Week 7 | 4 |
| Week 10 | 2 |
| Week 13 | 2 |
| Week 16 | 1 |
| Week 19 | 2 |
| Week 22 | 0 |
| Week 25 | 0 |
| Week 37 | 0 |
| Week 49 | 0 |
| Week 61 | 0 |
| Week 73 | 0 |
Collected over All cause mortality, non-SAEs and SAEs were collected up to 2 years.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Docetaxel 75 mg/m^2 | 25/34 (73.5%) | 16/34 (47.1%) | 31/34 (91.2%) |
| Feladilimab 80 mg Plus Docetaxel 75 mg/m^2 | 62/70 (88.6%) | 34/70 (48.6%) | 66/70 (94.3%) |
| Event | Docetaxel 75 mg/m^2 | Feladilimab 80 mg Plus Docetaxel 75 mg/m^2 |
|---|---|---|
| PneumoniaInfections and infestations | 6/34 | 7/70 |
| Febrile neutropeniaBlood and lymphatic system disorders | 3/34 | 4/70 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/34 | 3/70 |
| Diarrhoea infectiousInfections and infestations | 1/34 | 0/70 |
| Lung abscessInfections and infestations | 1/34 | 0/70 |
| Pneumocystis jirovecii pneumoniaInfections and infestations | 1/34 | 0/70 |
| Pneumonia mycoplasmalInfections and infestations | 1/34 | 0/70 |
| AnaemiaBlood and lymphatic system disorders | 1/34 | 2/70 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 1/34 | 2/70 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 1/34 | 1/70 |
| Event | Docetaxel 75 mg/m^2 | Feladilimab 80 mg Plus Docetaxel 75 mg/m^2 |
|---|---|---|
| NauseaGastrointestinal disorders | 6/34 | 26/70 |
| AnaemiaBlood and lymphatic system disorders | 7/34 | 24/70 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 4/34 | 23/70 |
| AstheniaGeneral disorders | 10/34 | 22/70 |
| AlopeciaSkin and subcutaneous tissue disorders | 7/34 | 20/70 |
| Decreased appetiteMetabolism and nutrition disorders | 4/34 | 19/70 |
| FatigueGeneral disorders | 5/34 | 17/70 |
| DiarrhoeaGastrointestinal disorders | 8/34 | 16/70 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/34 | 14/70 |
| ConstipationGastrointestinal disorders | 2/34 | 13/70 |
| Age, Continuous(years) | Docetaxel 75 mg/m^2 | Feladilimab 80 mg Plus Docetaxel 75 mg/m^2 | Total |
|---|---|---|---|
| Mean | 62.6 ± 10.48 | 64.4 ± 9.11 | 63.8 ± 9.57 |
| Age, Customized(Participants) | Docetaxel 75 mg/m^2 | Feladilimab 80 mg Plus Docetaxel 75 mg/m^2 | Total |
|---|---|---|---|
| 18-64 | 22 | 31 | 53 |
| 65-74 | 7 | 28 | 35 |
| 75-84 | 5 | 11 | 16 |
| >=85 | 1 | 0 | 1 |
| Sex: Female, Male(Participants) | Docetaxel 75 mg/m^2 | Feladilimab 80 mg Plus Docetaxel 75 mg/m^2 | Total |
|---|---|---|---|
| Female | 8 | 17 | 25 |
| Male | 27 | 53 | 80 |
| Ethnicity (NIH/OMB)(Participants) | Docetaxel 75 mg/m^2 | Feladilimab 80 mg Plus Docetaxel 75 mg/m^2 | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 2 |
| Not Hispanic or Latino | 35 | 67 | 102 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Region of Enrollment(participants) | Docetaxel 75 mg/m^2 | Feladilimab 80 mg Plus Docetaxel 75 mg/m^2 | Total |
|---|---|---|---|
| Canada | 3 | 0 | 3 |
| South Korea | 4 | 5 | 9 |
| Netherlands | 0 | 3 | 3 |
| Sweden | 0 | 2 | 2 |
| Romania | 2 | 9 | 11 |
| United States | 5 | 7 | 12 |
| Poland | 1 | 3 | 4 |
| Italy | 4 | 7 | 11 |
| France | 6 | 9 | 15 |
| Germany | 3 | 7 | 10 |
| Spain | 4 | 13 | 17 |
| Russia | 3 | 5 | 8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · www.gsk.com
Ran from Jan 2019 to primary completion in Sep 2021, 31 months.
Results were first posted in Jan 2023, 1 year 3 months after primary completion.
Of 179 industry-sponsored phase 2 interventional studies under Neoplasms, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 68. This study's 31 months is below that.
Counting every sponsor, half of 514 studies reached it within 52 months; a quarter within 33 and three quarters within 92.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Feladilimab